Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors

Inclusion Criteria: * Histologically confirmed solid tumor, including melanoma or renal cell carcinoma * Metastatic or unresectable disease * Must have evidence of residual, recurrent, or metastatic disease by radiography * Measurable disease * At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques (CT scan, MRI, or x-ray) OR ≥ 10 mm by spiral CT scan * Must show clear evidence of disease progression within the lesion if the only site of measurable disease is within a previously irradiated volume * Standard curative or palliative measures do not exist OR are no longer effective * No history of or known brain metastases * Performance status - ECOG 0-1 * At least 3 months * WBC ≥ 3,000/mm\^3 * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * AST and ALT ≤ 2.5 times upper limit of normal (ULN) * Bilirubin normal * Creatinine ≤ 1.5 times ULN * Creatinine clearance ≥ 50 mL/min * No symptomatic congestive heart failure * No unstable angina pectoris * No cardiac arrhythmia * Fasting cholesterol ≤ 350 mg/dL\* * Triglycerides ≤ 400 mg/dL\* * Not pregnant or nursing * Negative pregnancy test * Fertile female patients must use effective contraception for ≥ 1 month before, during, and for ≥ 3 months after completion of study treatment (during and for ≥ 3 months after completion of study treatment for male patients) * No history of allergic reaction attributed to compounds of similar chemical or biological composition to study drugs * No ongoing or active bacterial or viral infection * No psychiatric illness or social situation that would preclude study compliance * No dementia or altered mental status that would preclude giving informed consent * No other uncontrolled illnesses * More than 3 weeks since prior immunotherapy * Prior biological therapy (e.g., interferon or interleukin 2, vaccine, antibody-based and tyrosine kinase inhibitors) allowed * No concurrent prophylactic hematopoietic colony-stimulating factors except for epoetin alfa * No prior cytotoxic chemotherapy * No prior bryostatin 1, temsirolimus, everolimus, or AP23573 for this malignancy * More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) * No concurrent steroids except for topical or inhaled use * No other concurrent experimental agents * No prior radiotherapy to \> 25% of bone marrow * More than 3 weeks since prior radiotherapy * More than 3 weeks since prior major surgery, including nephrectomy * Minor surgical procedures allowed * Recovered from prior therapy * More than 3 weeks since prior other anticancer investigational agents * Concurrent CYP3A4 inducers or inhibitors allowed provided patient has been on a stable dose for ≥ 1 week before study entry * No concurrent combination antiretroviral therapy for HIV-positive patients * No other concurrent antineoplastic agents or therapies